- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03393286
ZIKAlliance Children Cohort (ZIKAllianceCH) (ZIKAllianceCH)
Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy
Study Overview
Status
Conditions
Detailed Description
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. The study will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome.
The study will also determine the ZIKV maternal to child transmission rate and evaluate co-factors or effect modifiers that account for the large variability seen in the preliminary absolute risk estimates derived from population figures and reporting of microcephaly in different states in Brazil and across Latin America.
The study will carry out a pregnant women (PW) multicentre cohort study in areas across Latin America and the Caribbean. Women will be enrolled early in pregnancy and followed every 4 weeks, in connection with their routine antenatal care visits. At each visit, urine and blood samples will be collected, tested and stored.
Among PW reporting recent or current undifferentiated fever/rash syndrome at any point in time, the acute illness episode will be characterized in greater detail. PW with suspected ZIKV infection (i.e. meeting the Pan American Health Organization (PAHO) clinical case definition) during pregnancy will be managed according to national protocols. Irrespective of symptoms, pregnant women will be followed prospectively and revisited at birth (or after abortion) for a detailed documentation of the outcome of their pregnancy.
Live newborns will receive a detailed neonatal examination. In the course of examination of the newborns, biological samples will be collected and stored. Other potential causes of congenital abnormalities (TORCHS infections in the mother, toxic substances, chromosomal abnormalities), and potential effect modifiers (for example past flavivirus infections/vaccinations, socio-economic status) will also be assessed.
With appropriate counselling and consent, biological samples of newborns with severe abnormalities, deceased newborns, stillborn babies, and aborted foetuses from ZIKV-infected mothers will be collected to help elucidate the aetiological contribution of ZIKV in neurological and other congenital malformations.
Children of women infected with ZIKV during pregnancy - and a subset of the children born to uninfected women - will be followed prospectively after birth for the assessment of neuro-developmental milestones.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Guaqui, Bolivia
- Sosecali Ltd. (SOSE)
-
-
-
-
-
Recife, Brazil
- Fundacao Oswaldo Cruz (FIOCRUZ)
-
Rio de Janeiro, Brazil
- Fundacao Oswaldo Cruz (FIOCRUZ)
-
São Paulo, Brazil
- University of Sao Paulo
-
-
-
-
-
Bucaramanga, Colombia
- Industrial University of Santander (UIS)
-
-
-
-
-
Havana, Cuba
- Pedro Kouri Institute (IPK)
-
-
-
-
-
Pointe-à-Pitre, Guadeloupe
- Inserm
-
-
-
-
-
Guadalajara, Mexico
- IMSS Mexico (IMSS)
-
Mérida, Mexico
- National Institute of Public Health (INSP)
-
-
-
-
-
Valencia, Venezuela
- Universidad de Carabobo / UMC Groningen (UMCG)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Born within the Pregnant Woman cohort
- Born to mothers with confirmed ZIKA
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Congenital Abnormalities detected after birth as defined by the evolving definition of the congenital zika syndrome
Time Frame: Birth
|
Birth
|
Hearing abnormalities measured after birth
Time Frame: Between birth and 2 years
|
Between birth and 2 years
|
Visual abnormalities measured after birth
Time Frame: Between birth and 2 years
|
Between birth and 2 years
|
Developmental / cognitive abnormalities measured by the Ages and Stages 3rd Edition (ASQ3)
Time Frame: Between birth and 2 years
|
Between birth and 2 years
|
Developmental / cognitive abnormalities measured by the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 734548CH (EC | H2020 | RIA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
- The ZIKAlliance birth cohort is part of the 3 European Commission (EC) funded Zika consortia. The data are intended to be shared after the individual cohort data is analyzed and published.
- The ZIKAlliance birth cohort is part of the WHO-moderated IPD meta-analysis Consortium. The data are intended to be shared after the individual cohort data is analyzed and published.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Zika Virus
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...CompletedPrevention of Zika Infection | Zika-Specific Immune ResponseUnited States
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
Kathryn StephensonNational Institute of Allergy and Infectious Diseases (NIAID); Walter Reed...Completed
-
Valneva Austria GmbHRecruitingZika | Zika Virus InfectionUnited States
-
Emergent BioSolutionsCompletedZika Virus Infection | Zika Virus DiseaseCanada
-
National Institute of Allergy and Infectious Diseases...CompletedPrevention of Zika Infection | Zika-Specific Immune ResponseUnited States
-
Northwestern UniversityPontificia Universidad Catolica Madre y MaestraWithdrawnZika Virus Symptoms and the Associated ExanthemaDominican Republic
-
Children's National Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationChild Development | Congenital Zika Syndrome | Zika Virus | Congenital InfectionUnited States, Colombia
-
National Institute of Allergy and Infectious Diseases...Completed